A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.

Eli Lilly announced that the company’s psoriasis drug Taltz overcame Johnson & Johnson’s Tremfya in a head-to-head study.

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.

Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Johnson & Johnson reported better-than-expected fourth-quarter revenue, helped by strong demand for the company’s drugs to treat cancer and psoriasis.

Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Boston Pharmaceuticals licenses a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.

Europe approved a fifth copy of AbbVie’s $18-billion-a-year biologic Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.